Clinical Data Data backs GSK’s ovarian cancer blockbuster hopes PharmaphorumGSK's B7-H4-targeting ADC Mo-Rez chalks up impressive results in ovarian and endometrial cancer, prompting a major phase 3 trials programme.Clinical DataOncologyRead full story pharminent April 13, 2026 (Last updated: April 13, 2026) Pharmaphorum GSK’s B7-H4-targeting ADC Mo-Rez chalks up impressive results in ovarian and endometrial cancer, prompting a major phase 3 trials programme. Clinical DataOncologyRead full story Post navigation Previous: FDA issues complete response letter to Replimune’s RP1 for melanomaNext: FDA issues complete response letter to Replimune’s RP1 for melanoma Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
